2025 ACMT Psychedelics Seminar October 10, 2025 10:00 AM – October 17, 2025 5:00 PM  |  Virtual

2-Day Live Seminar

October 10 & 17, 2025
10am-5pm ET
Virtual

Register

Explore the evolving science, clinical applications, and complex realities of psychedelics in the 2025 ACMT Psychedelics Seminar, a two-day virtual course designed for healthcare professionals, clinicians, and toxicologists.

Held over two Fridays in October, this immersive course provides a comprehensive foundation in the pharmacology, toxicology, and therapeutic uses of psychedelics, while critically examining their place in today’s healthcare landscape.

Course Themes:

  • Psychedelics 101: Pharmacology & Foundations
  • Clinical Applications
  • Adverse Effects, Safety, and Ethics
  • Policy, Practice & Real-World Implementation

Over two days, participants will explore the pharmacology of classic psychedelics—including psilocybin, ayahuasca, mescaline, and LSD—as well as the therapeutic potential of ketamine, ibogaine, and MDMA. The course will review current evidence on psychedelics for treating substance use disorders, depression, PTSD, anxiety, and emerging areas such as dementia and Parkinson’s disease.

Attendees will also examine the use of psychedelics in special populations, including in palliative and end-of-life care, pregnancy, and breastfeeding. Sessions will address the shifting legal and regulatory landscape, highlighting lessons from Oregon and Colorado’s psilocybin programs, the rapid growth of ketamine clinics, and the realities of microdosing.

Throughout the seminar, faculty will emphasize safety, adverse effects, drug interactions, and emerging designer substances, while engaging participants in critical conversations about indigenous knowledge, ethical access, and responsible integration of psychedelics into modern healthcare.

Target Audience
This seminar is designed for healthcare professionals and researchers interested in medical toxicology, addiction medicine, and the emerging role of psychedelics in therapeutic settings, including:

  • Physicians
  • Pharmacists
  • Nurses and Nurse Practitioners
  • Physician Assistants
  • Clinicians and Specialists in Poison Information
  • Addiction Counselors and Mental Health Professionals
  • Researchers
  • Fellows, Residents, and Students

Learning Objectives:

  1. Describe the pharmacology and toxicology of classic and emerging psychedelics, including psilocybin, ketamine, ibogaine, and MDMA.
  2. Evaluate current research on the clinical use of psychedelics in treating substance use disorders, mental health conditions, palliative care, and special populations.
  3. Analyze the adverse effects and safety considerations associated with psychedelic use.
  4. Identify practical strategies, legal factors, ethical considerations, and systemic barriers to integrating psychedelic-assisted therapies into existing treatment frameworks.

Continuing Education

10.0 Continuing Education credits available for Physicians (CME), Pharmacists (CNE) and Nurses (CNE)

Register